HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $25

Benzinga Newsdesk www.benzinga.com Neutral 78.8%

Neg 0% Neu 78.8% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $30 to $25.